# Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)

Source: https://onco.cc/trials/nct07070622/  
OnCo record `nct07070622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by West China Hospital, now recruiting.

## Summary

Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR) is a phase 3, randomised interventional study registered as NCT07070622 by West China Hospital, with a registry enrolment figure of 186 participants, started 2024-11-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: patients were assigned to receive TNT or iTNT management. Conditions listed: Rectal Cancer. Primary outcome: organ preservation rate，OPR. Colorectal eligibility wording from the registry: "rectal adenocarcinoma confirmed by pathology and pMMR/MSS by immunohistochemistry and/or genetic testing;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: OPLAR
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07070622
- Phase: 3
- Setting: Planed Organ Preservation for Early- and Intermediate-risk Low Rectal Cancer With Good Response to Neoadjuvant Chemotherapy
- Sponsor: West China Hospital
- Enrolled: 186

## Sources

- ClinicalTrials.gov NCT07070622: https://clinicaltrials.gov/study/NCT07070622

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07070622.json